

Pharmacy Benefact

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Number 508 • February 2015

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Actavis Pharma Company that the shortage of CO Diclo-Miso 75 mg/200 mcg Enteric-Coated Tablet (DIN 02397153) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **March 9, 2015**.

DICLOFENAC SODIUM/ MISOPROSTOL

75 MG * 200 MCG ORAL ENTERIC-COATED TABLET

00002397153	CO DICLO-MISO	APH	\$ 0.6179
00002229837	ARTHROTEC-75	PFI	\$ 0.8362

Alberta Blue Cross has been advised by Apotex Inc., Mylan Pharmaceuticals ULC and Sandoz Canada Inc. that the shortages of Apo-Nitroglycerin 0.4 mg/dose Sublingual Spray (DIN 02393433), Mylan-Nitro 0.4 mg/dose Sublingual Spray (DIN 02243588) and Rho-Nitro Pumpspray 0.4 mg/dose Sublingual Spray (DIN 02238998) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **March 9, 2015**.

NITROGLYCERIN

0.4 MG / DOSE SUBLINGUAL METERED DOSE SPRAY

00002393433	APO-NITROGLYCERIN	APX	\$ 0.0421
00002243588	MYLAN-NITRO	MYP	\$ 0.0421
00002238998	RHO-NITRO PUMPSPRAY	SDZ	\$ 0.0421
00002231441	NITROLINGUAL PUMPSPRAY	SAV	\$ 0.0747

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage of Novo-Cilazapril 2.5 mg Tablet (DIN 02266369) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **March 9, 2015**.

CILAZAPRIL

2.5 MG ORAL TABLET

00002291142	APO-CILAZAPRIL	APX	\$0.1795
00002283786	MYLAN-CILAZAPRIL	MYP	\$0.1795
00002266369	NOVO-CILAZAPRIL	TEV	\$0.1795
00002280450	PMS-CILAZAPRIL	PMS	\$0.1795
00001911473	INHIBACE	HLR	\$ 0.7436

continued on next page ...

continued from previous page ...

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Quinapril 10 mg Tablet (DIN 02248500) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **March 9, 2015**.

QUINAPRIL

10 MG (BASE) ORAL TABLET

00002248500	APO-QUINAPRIL	APX	\$ 0.6867
00001947672	ACCUPRIL	PFI	\$ 0.9110

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage of Teva-Atenolthalidone 50 mg/25 mg Tablet (DIN 02302918) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **March 9, 2015**.

ATENOLOL/ CHLORTHALIDONE

50 MG * 25 MG ORAL TABLET

00002248763	APO-ATENIDONE	APX	\$ 0.3195
00002302918	TEVA-ATENOLTHALIDONE	TEV	\$ 0.3195
00002049961	TENORETIC 50/25	AZC	\$ 0.6773

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)



®The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ABC 82320.508 2015/02